{"id":"W3204308533","doi":"10.1016/j.annonc.2021.08.1063","title":"541P Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with previously treated advanced solid tumours","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"EMD Serono; Genentech; Astellas Pharma; Eisai; Flatiron Health; MacroGenics; Tarveda Therapeutics; Pfizer; Incyte; BeiGene; Clovis Oncology; Astex Pharmaceuticals; Karyopharm Therapeutics; Exelixis; Revolution Medicines; Regeneron Pharmaceuticals; GlaxoSmithKline; G1 Therapeutics; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Array BioPharma; Mersana Therapeutics; Merck KGaA; Servier; Gilead Sciences","keywords":"Medicine; VEGF receptors; Blocking (statistics); Antibody; Blocking antibody; Pharmacology; Cancer research; Oncology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002329619,0.0002864922,0.0006773121,0.0001515152,0.0001574748,0.0002711681,0.0001448406,0.0002138408,0.001483236],"category_scores_gemma":[0.0002887787,0.0001261023,0.0003345693,0.00020735,0.0001333507,0.000237803,0.0001315922,0.000656542,0.000313395],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003583444,"about_ca_system_score_gemma":0.0002969565,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007010365,"about_ca_topic_score_gemma":0.002477616,"domain_scores_codex":[0.9999368,0.00001693261,0.000004220261,0.00001177873,0.00001049504,0.0000198079],"domain_scores_gemma":[0.9999264,0.00001830585,0.00001185496,0.000002565001,0.000003885674,0.00003691829],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2723195,0.005132314,0.08615661,0.001314724,0.001711884,0.00365062,0.0003376479,0.003459594,0.1201205,0.0005788307,0.01256184,0.4926559],"study_design_scores_gemma":[0.06752759,0.2606108,0.5591277,0.0002888833,0.003711414,0.01037739,0.0004231316,0.007859978,0.03684077,0.0009391238,0.05220614,0.00008699671],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889807,0.006079944,0.000276549,0.0004875069,0.000111471,0.00007275848,0.0002353796,0.00004910856,0.003706675],"genre_scores_gemma":[0.995637,0.001721112,0.0002815057,0.0002639233,0.00005709811,0.0000432023,0.0003532036,0.000005619313,0.001637285],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001483236,"threshold_uncertainty_score":0.004961908,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04145827966138752,"score_gpt":0.3893845382024157,"score_spread":0.3479262585410282,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}